HomeCompareCLVLY vs MO

CLVLY vs MO: Dividend Comparison 2026

CLVLY yields 0.36% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLY wins by $225.4K in total portfolio value
10 years
CLVLY
CLVLY
● Live price
0.36%
Share price
$7.24
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$305.5K
Annual income
$199,327.02
Full CLVLY calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — CLVLY vs MO

📍 CLVLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLY + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLY
Annual income on $10K today (after 15% tax)
$30.66/yr
After 10yr DRIP, annual income (after tax)
$169,427.97/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, CLVLY beats the other by $143,792.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLY + MO for your $10,000?

CLVLY: 50%MO: 50%
100% MO50/50100% CLVLY
Portfolio after 10yr
$192.8K
Annual income
$114,743.09/yr
Blended yield
59.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

CLVLY
No analyst data
Altman Z
17.2
Piotroski
5/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLY buys
0
MO buys
0
No recent congressional trades found for CLVLY or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLYMO
Forward yield0.36%6.36%
Annual dividend / share$0.03$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%22.6%
Portfolio after 10y$305.5K$80.1K
Annual income after 10y$199,327.02$30,159.17
Total dividends collected$276.6K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CLVLY vs MO ($10,000, DRIP)

YearCLVLY PortfolioCLVLY Income/yrMO PortfolioMO Income/yrGap
1← crossover$10,772$72.13$10,570$780.30+$202.00CLVLY
2$11,671$145.24$11,381$1,032.90+$290.00CLVLY
3$12,783$294.14$12,535$1,392.73+$248.00CLVLY
4$14,279$602.13$14,193$1,920.91+$86.00CLVLY
5$16,536$1,257.27$16,618$2,723.68$82.00MO
6$20,415$2,721.45$20,263$3,993.80+$152.00CLVLY
7$28,124$6,280.07$25,936$6,098.36+$2.2KCLVLY
8$46,264$16,171.07$35,166$9,775.01+$11.1KCLVLY
9$99,224$49,721.74$51,026$16,597.78+$48.2KCLVLY
10$305,497$199,327.02$80,113$30,159.17+$225.4KCLVLY

CLVLY vs MO: Complete Analysis 2026

CLVLYStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLY Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this CLVLY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLY vs SCHDCLVLY vs JEPICLVLY vs OCLVLY vs KOCLVLY vs MAINCLVLY vs PMCLVLY vs BTICLVLY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.